Citeline: Rapid Nexus Bets On Regeneration To Heal Wounds, Stop Amputations, Starting In VA Health Systems

Rapid Nexus hopes its regenerative wound-healing system can ease the burden of diabetic foot ulcers and amputations. Backed by early clinical data and $3.8m in seed funding, the start-up is targeting the VA as a launchpad into a $6.5bn US market, with FDA clearance expected later this year. California-based start-up Rapid Nexus wants to transform treatment for diabetic foot ulcers with its two-part regenerative wound-healing technology designed to treat open sores and prevent amputations, starting with patients at the Veterans Affairs system. Read full article